Dyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics (Nasdaq:DYN) announced participation in several investor conferences focused on healthcare in May and June 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dyne Therapeutics (Nasdaq:DYN) announced participation in several investor conferences focused on healthcare in May and June 2026.
Management will join fireside chats at the RBC Capital Markets Global Healthcare Conference on May 20 and the Jefferies Global Healthcare Conference on June 3 in New York, plus investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami.
Live webcasts and 90-day replays of the fireside chats will be available in the Investors & Media section of Dyne’s website.
Details
News Market Reaction – DYN
On May 13, the day this news came out, DYN closed 0.38% above the previous close.
Data tracked by StockTitan Argus for the May 13 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:
- 2026 RBC Capital Markets Global Healthcare Conference, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY
- 2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NY
- Goldman Sachs 47th Annual Global Healthcare Conference 2026, hosting meetings on Tuesday, June 9, 2026 in Miami, FL
A live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.